Bio-Rad Laboratories (BIO) FY2022 results: revenue $2.8 billion, down 4.1% on the year
Bio-Rad Laboratories, Inc. (BIO) reported revenue of $2.8 billion for fiscal 2022, the year ended 31 December 2022, down 4.1% on the year before. Net income was -$3.6 billion, and diluted earnings per share $-121.79. The figures are the company's own, from the 10-K it filed with the SEC on 17 February 2023.
Revenue
$2.8 billion
-4.1% on the year
FY2015FY2022
Operating margin
17.2%
17.1% a year earlier
FY2015FY2022
Net income
-$3.6 billion
FY2015FY2022
Diluted EPS
-$121.79
FY2015FY2022
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2022
FY2021
FY2020
On the year
Last 8 years
Operating cash flow
194
669
585
-71.0%
Capital expenditure
113
134
109
-15.7%
Free cash flow
81.7
536
476
-84.8%
Free cash flow margin
2.9%
18.3%
18.7%
Cash from investing
-1,208
-797
-69.9
Cash from financing
974
-55.4
-523
Depreciation and amortisation
137
138
139
-0.2%
Share-based compensation
60.9
51.2
41.6
+18.9%
Buybacks
216
50.0
100
+331.4%
Diluted shares, weighted
30m
30m
30m
-1.4%
Balance sheet
$ million
FY2022
FY2021
FY2020
On the year
Last 8 years
Shareholders' equity
9,615
13,667
9,880
-29.6%
Debt
1,198
10.5
14.1
+11,291.6%
Operating lease liabilities
154
176
175
-12.7%
Finance lease liabilities
10.1
10.5
11.0
-3.8%
Other liabilities
2,525
3,912
2,892
-35.5%
Total liabilities and equity
13,502
17,776
12,973
-24.0%
Fixed assets
499
512
491
-2.5%
Goodwill
406
347
292
+17.0%
Intangible assets
332
254
199
+30.8%
Investments
10,187
14,786
9,890
-31.1%
Trading assets
323
443
0.0
-27.2%
Cash and equivalents
434
471
662
-7.8%
Receivables
495
424
419
+16.8%
Inventory
719
572
622
+25.7%
Other assets
106
n/a
396
Total assets
13,502
17,776
12,973
-24.0%
10-K for the year ended 31 December 2022, filed 17 February 2023: the filing.